Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis

被引：0
|
作者：
Aronne, L. [1 ]
Harris, M. S. [2 ]
Roberts, M. S. [2 ]
Suschak, J. [2 ]
Tomah, S. [2 ]
He, L. [2 ]
Yang, J. [2 ]
Frias, J. P. [3 ]
Browne, S. K. [2 ]
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Altimmune Inc, Gaithersburg, MD USA
[3] Veloc Clin Res, Los Angeles, CA USA
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
60
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [41] THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA
    Barratt, Jonathan
    Tumlin, James A.
    Suzuki, Yusuke
    Kao, Amy
    Aydemir, Aida
    Zima, Yulia
    Appel, Gerald
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 139 - 139
  • [42] BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
    Van der Heijde, D.
    Baraliakos, X.
    Dougados, M.
    Brown, M.
    Poddubnyy, D.
    Van den Bosch, F.
    Haroon, N.
    Xu, H.
    Tomita, T.
    Gensler, L. S.
    Oortgiesen, M.
    Fleurinck, C.
    Vaux, T.
    Marten, A.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 12 - 13
  • [43] Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis
    Suschak, John
    Georges, Bertrand
    Browne, Sarah
    Alonso, Cristina
    Roberts, M. Scot
    Harris, M. Scott
    JOURNAL OF HEPATOLOGY, 2024, 80 : S529 - S529
  • [44] Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome-Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS)
    Jeppesen, Palle B.
    Pertkiewicz, Marek
    Seidner, Douglas L.
    O'Keefe, Stephen
    Heinze, Hartmut
    Joelsson, Bo
    GASTROENTEROLOGY, 2011, 140 (05) : S146 - S146
  • [45] A triple GIP, GLP-1 and glucagon receptor agonist, retatrutide, decreases inflammatory CV risk biomarkers in people with overweight or obesity, with or without type 2 diabetes
    Ruotolo, G.
    Harris, C.
    Lin, Y.
    Thomas, M. K.
    Qu, Y.
    Wilson, J.
    Duffin, K.
    Hartman, M. L.
    Coskun, T.
    Milicevic, Z.
    Haupt, A.
    DIABETOLOGIA, 2024, 67 : S82 - S82
  • [46] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
    Buse, JB
    Rubin, CJ
    Frederich, R
    Viraswami-Appanna, K
    Lin, KC
    Montoro, R
    Shockey, G
    Davidson, JA
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1181 - 1195
  • [47] The effect of tesofensine on weight loss, appetite, physical activity and QOL in obese subjects. Results from a 24-week randomised, double-blind placebo-controlled trial
    Astrup, Arne
    Madsbad, Sten
    Breum, Leif
    Kroustrup, Jens P.
    Jensen, Thomas J.
    Larsen, Thomas M.
    DIABETES, 2008, 57 : A739 - A739
  • [48] Liraglutide, a Once-Daily Human GLP-1 Analog, Reverses Indices of Prediabetes in Obese Subjects: A Randomized Placebo-Controlled 20-Week Trial
    Finer, Nick
    Al Hakim, Mazin
    Astrup, Arne
    Harper, Angela
    Lean, Mike
    Niskanen, Leo
    Rasmussen, Mads F.
    Rissanen, Aila
    Roessner, Stephan
    Van Gaal, Luc
    DIABETES, 2009, 58 : A443 - A444
  • [49] Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial
    Ebdrup, Bjorn H.
    Broberg, Brian V.
    Ishoy, Pelle L.
    Bak, Nikolaj
    Andersen, Ulrik B.
    Jorgensen, Niklas R.
    Holst, Jens J.
    Knop, Filip K.
    Glenthoj, Birte Y.
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1327 - 1328
  • [50] Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
    Mojca Jensterle
    Simona Ferjan
    Tadej Battelino
    Jernej Kovač
    Saba Battelino
    Dušan Šuput
    Andrej Vovk
    Andrej Janež
    Trials, 22
12345